降眼压药物的持久性和耐受性：青光眼管理中的基于人群的证据 - Suppr

Suppr

超能文献

Persistency and tolerability of ocular hypotensive agents: population-based evidence in the management of glaucoma.

作者信息

Schwartz Gail F

机构信息

Greater Baltimore Medical Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, USA.

出版信息

Am J Ophthalmol. 2004 Jan;137(1 Suppl):S1-2. doi: 10.1016/j.ajo.2003.10.029.

DOI:10.1016/j.ajo.2003.10.029

PMID:14697908

Abstract

摘要

相似文献

Persistency and tolerability of ocular hypotensive agents: population-based evidence in the management of glaucoma.

Am J Ophthalmol. 2004 Jan;137(1 Suppl):S1-2. doi: 10.1016/j.ajo.2003.10.029.

Persistency with glaucoma medication.

Am J Ophthalmol. 2004 Dec;138(6):1093-4; author reply 1094. doi: 10.1016/j.ajo.2004.05.002.

Measuring persistency and intraocular pressure-controlled days in patients receiving topical glaucoma medications.

Am J Manag Care. 2002 Aug;8(10 Suppl):S278-80.

[Compliance in glaucoma].

Oftalmologia. 2008;52(3):7-9.

Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data.

Am J Manag Care. 2002 Aug;8(10 Suppl):S255-61.

[Glaucoma and dry eye. Current concepts and future perspectives].

Ophthalmologe. 2013 Dec;110(12):1155-9. doi: 10.1007/s00347-012-2675-z.

A myth of ophthalmic beta-blockers therapy.

Graefes Arch Clin Exp Ophthalmol. 2009 Dec;247(12):1721; author reply 1723. doi: 10.1007/s00417-009-1164-9. Epub 2009 Aug 20.

[General substance classification and pharmacology of glaucoma].

Ophthalmologe. 2013 Dec;110(12):1149-54. doi: 10.1007/s00347-012-2676-y.

Patient persistency with topical ocular hypotensive therapy in a managed care population.

Am J Ophthalmol. 2004 Jan;137(1 Suppl):S3-12. doi: 10.1016/j.ajo.2003.10.035.

Modern alchemy: fixed combinations of glaucoma drugs.

Am J Ophthalmol. 2005 Jul;140(1):125-6. doi: 10.1016/j.ajo.2005.03.034.

引用本文的文献

Pharmacotherapy and Adherence Issues in Treating Elderly Patients with Glaucoma.

Drugs Aging. 2015 Jul;32(7):569-81. doi: 10.1007/s40266-015-0282-9.

Persistence on prostaglandin ocular hypotensive therapy: an assessment using medication possession and days covered on therapy.

BMC Ophthalmol. 2010 Mar 2;10:5. doi: 10.1186/1471-2415-10-5.

Compliance: clear communication's critical.

Br J Ophthalmol. 2005 Oct;89(10):1370. doi: 10.1136/bjo.2005.066175.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Persistency and tolerability of ocular hypotensive agents: population-based evidence in the management of glaucoma.

Am J Ophthalmol. 2004 Jan;137(1 Suppl):S1-2. doi: 10.1016/j.ajo.2003.10.029.

Persistency with glaucoma medication.

Am J Ophthalmol. 2004 Dec;138(6):1093-4; author reply 1094. doi: 10.1016/j.ajo.2004.05.002.

Measuring persistency and intraocular pressure-controlled days in patients receiving topical glaucoma medications.

Am J Manag Care. 2002 Aug;8(10 Suppl):S278-80.

[Compliance in glaucoma].

Oftalmologia. 2008;52(3):7-9.

Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data.

Am J Manag Care. 2002 Aug;8(10 Suppl):S255-61.

[Glaucoma and dry eye. Current concepts and future perspectives].

Ophthalmologe. 2013 Dec;110(12):1155-9. doi: 10.1007/s00347-012-2675-z.

A myth of ophthalmic beta-blockers therapy.

Graefes Arch Clin Exp Ophthalmol. 2009 Dec;247(12):1721; author reply 1723. doi: 10.1007/s00417-009-1164-9. Epub 2009 Aug 20.

[General substance classification and pharmacology of glaucoma].

Ophthalmologe. 2013 Dec;110(12):1149-54. doi: 10.1007/s00347-012-2676-y.

Patient persistency with topical ocular hypotensive therapy in a managed care population.

Am J Ophthalmol. 2004 Jan;137(1 Suppl):S3-12. doi: 10.1016/j.ajo.2003.10.035.

Modern alchemy: fixed combinations of glaucoma drugs.

Am J Ophthalmol. 2005 Jul;140(1):125-6. doi: 10.1016/j.ajo.2005.03.034.

引用本文的文献

Pharmacotherapy and Adherence Issues in Treating Elderly Patients with Glaucoma.

Drugs Aging. 2015 Jul;32(7):569-81. doi: 10.1007/s40266-015-0282-9.

Persistence on prostaglandin ocular hypotensive therapy: an assessment using medication possession and days covered on therapy.

BMC Ophthalmol. 2010 Mar 2;10:5. doi: 10.1186/1471-2415-10-5.

Compliance: clear communication's critical.

Br J Ophthalmol. 2005 Oct;89(10):1370. doi: 10.1136/bjo.2005.066175.